Type I interferon/STAT1 signaling regulates UBE2M-mediated antiviral innate immunity in a negative feedback manner

Xianghui Kong,Xinliang Lu,Shibo Wang,Jiayue Hao,Danfeng Guo,Hao Wu,Yu Jiang,Yi Sun,Jianli Wang,Gensheng Zhang,Zhijian Cai
DOI: https://doi.org/10.1016/j.celrep.2023.112002
IF: 8.8
2023-01-01
Cell Reports
Abstract:Type I interferon (IFN-I) signaling is central to inducing antiviral innate immunity. However, the mechanisms for IFN-I signaling self-regulation are still largely unknown. Here, we report that RNA virus-infected macro-phages with UBE2M deficiency produced decreased IFN-I expression in a RIG-I-dependent manner, causing an aggravated viral infection. Mechanistically, UBE2M inhibits RIG-I degradation by preventing the interac-tion of RIG-I and E3 ligase STUB1, resulting in antiviral IFN-I signaling activation. Simultaneously, IFN-I signaling-activated STAT1 facilitates the transcription of Trim21, leading to increased UBE2M degradation and blunted antiviral immunity. Translationally, oral administration of milk-derived extracellular vesicles con-taining RING domain-truncated TRIM21 (TRIM21-DRING) lacking E3 ligase activity efficiently transfers TRIM21-DRING into macrophages. TRIM21-DRING suppresses UBE2M degradation by competitively bind-ing to UBE2M with TRIM21, thereby enhancing antiviral immunity. Overall, we reveal a negative feedback loop of IFN-I signaling and develop a reagent to improve innate immunity against RNA viruses.
What problem does this paper attempt to address?